Cunningham Patrick A. 4

Research Summary

AI-generated summary

Updated

Aveanna (AVAH) CCO Patrick Cunningham Sells Shares

What Happened

  • Patrick A. Cunningham, Chief Compliance Officer of Aveanna Healthcare (AVAH), disposed of a total of 49,160 shares in three open-market/private sales to satisfy tax obligations from vested equity awards. The three transactions on Feb 17–19, 2026 generated aggregate proceeds of about $363,068.
  • Breakdown by trade: 12,759 shares on 2026-02-17 at $7.65 ($97,544); 17,965 shares on 2026-02-18 at $7.38 ($132,634); 18,436 shares on 2026-02-19 at $7.21 ($132,890). These were sales (not purchases).

Key Details

  • Transaction dates and reported prices:
    • 2026-02-17: 12,759 shares @ $7.65 — total $97,544 (footnote: weighted avg range $7.47–$7.97; F2).
    • 2026-02-18: 17,965 shares @ $7.38 — total $132,634 (footnote: weighted avg range $7.175–$7.53; F3).
    • 2026-02-19: 18,436 shares @ $7.21 — total $132,890 (footnote: weighted avg range $7.06–$7.29; F4).
  • Aggregate proceeds: ≈ $363,068 for 49,160 shares.
  • Reason: Footnote indicates these shares were automatically sold to satisfy the reporting person's tax withholding obligations related to vested equity awards (tax withholding / cashless sale; F1).
  • Sales were part of aggregate transactions handled by the company’s stock plan administrator; the filer can provide per-price details to SEC/stakeholders on request.
  • Shares owned after transaction: Not specified in the provided filing.
  • Filing timeliness: Report filed 2026-02-19 for transactions on 2026-02-17–19; filing appears timely (no late filing indicated).

Context

  • These were disposals to cover tax withholding tied to vesting (routine administrative sales), not open-market purchases — such sales generally reflect tax obligations rather than a clear buy/sell signal about the insider’s view of the company.
  • For retail investors: purchases by insiders typically carry more informational weight than routine withholding sales; this filing documents tax-related sales, not new stock acquisitions or option exercises for cash gain.